IgGenix flips the biology of allergy on its head: it finds the antibody that makes you sick, then rebuilds it into one that protects you.
https://yespress.io/iggenix-inc?utm_source=bluesky&utm_medium=social via Yespress - apply for company newsroom: yespress.io/newsroom
https://yespress.io/iggenix-inc?utm_source=bluesky&utm_medium=social via Yespress - apply for company newsroom: yespress.io/newsroom
IgGenix, Inc. - The Antibody That Learned to Switch Sides
A clinical-stage biotech re-engineering allergy-causing IgE antibodies into protective IgG. Inside SEQ SIFTER, the IGNX001 peanut trial, and $75M in funding.
yespress.io
August 17, 2026 at 3:09 AM
IgGenix flips the biology of allergy on its head: it finds the antibody that makes you sick, then rebuilds it into one that protects you.
https://yespress.io/iggenix-inc?utm_source=bluesky&utm_medium=social via Yespress - apply for company newsroom: yespress.io/newsroom
https://yespress.io/iggenix-inc?utm_source=bluesky&utm_medium=social via Yespress - apply for company newsroom: yespress.io/newsroom
IgGenix is using its new RNA-sequencing platform to accelerate the development of allergy treatments, starting with peanut allergy. #foodallergies
IgGenix Doses Final Participant in Phase 1 Study of Novel Peanut Allergy Treatment
First study using SEQ SIFTER™ antibody discovery platform.
snacksafely.com
September 3, 2025 at 2:54 PM
IgGenix is using its new RNA-sequencing platform to accelerate the development of allergy treatments, starting with peanut allergy. #foodallergies
A couple new updates on clinical trials in peanut allergy and immune diseases.
IgGenix Australia is recruiting in for a clinical trial of their treatment for peanut allergy. They isolated IgE mAbs and class-switched them to igG4 mAbs.
www.iggenix.com.au
pubmed.ncbi.nlm.nih.gov/39069172/
1/
IgGenix Australia is recruiting in for a clinical trial of their treatment for peanut allergy. They isolated IgE mAbs and class-switched them to igG4 mAbs.
www.iggenix.com.au
pubmed.ncbi.nlm.nih.gov/39069172/
1/
March 8, 2025 at 12:29 PM
A couple new updates on clinical trials in peanut allergy and immune diseases.
IgGenix Australia is recruiting in for a clinical trial of their treatment for peanut allergy. They isolated IgE mAbs and class-switched them to igG4 mAbs.
www.iggenix.com.au
pubmed.ncbi.nlm.nih.gov/39069172/
1/
IgGenix Australia is recruiting in for a clinical trial of their treatment for peanut allergy. They isolated IgE mAbs and class-switched them to igG4 mAbs.
www.iggenix.com.au
pubmed.ncbi.nlm.nih.gov/39069172/
1/
Great news from IgGenix, the company using its SEQ SIFTER platform to develop treatments for food allergies. They have uncovered antibodies implicated in Alpha-gal Syndrome, work providing insights that may lead to therapies and a cure. #foodallergies
snacksafely.com/2025/02/igge...
snacksafely.com/2025/02/igge...
IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress
Data highlight potential for new diagnostics and therapeutics targeting red meat allergy.
snacksafely.com
February 14, 2025 at 7:53 PM
Great news from IgGenix, the company using its SEQ SIFTER platform to develop treatments for food allergies. They have uncovered antibodies implicated in Alpha-gal Syndrome, work providing insights that may lead to therapies and a cure. #foodallergies
snacksafely.com/2025/02/igge...
snacksafely.com/2025/02/igge...
IgGenix to Showcase Groundbreaking Alpha-gal Antibody Discovery at 2025 AAAAI / WAO Congress#United_States#San_Diego#Monoclonal_Antibodies#IgGenix#Alpha-gal_Syndrome
IgGenix to Showcase Groundbreaking Alpha-gal Antibody Discovery at 2025 AAAAI / WAO Congress
IgGenix will reveal its innovative monoclonal antibody discoveries for Alpha-gal Syndrome at the 2025 AAAAI / WAO Joint Congress, enhancing our understanding of this red meat allergy.
third-news.com
February 10, 2025 at 3:06 PM
IgGenix to Showcase Groundbreaking Alpha-gal Antibody Discovery at 2025 AAAAI / WAO Congress#United_States#San_Diego#Monoclonal_Antibodies#IgGenix#Alpha-gal_Syndrome
🔗 The study is currently recruiting participants. To learn more and check your eligibility, visit- allergylife.com.au/iggenix
-𝘛𝘩𝘪𝘴 𝘪𝘴 𝘯𝘰𝘵 𝘢 𝘴𝘱𝘰𝘯𝘴𝘰𝘳𝘦𝘥 𝘱𝘰𝘴𝘵
𝘈𝘭𝘭𝘦𝘳𝘨𝘺 𝘓𝘪𝘧𝘦 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘴 𝘢𝘭𝘭𝘦𝘳𝘨𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥 𝘵𝘰 𝘬𝘦𝘦𝘱 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥.
-𝘛𝘩𝘪𝘴 𝘪𝘴 𝘯𝘰𝘵 𝘢 𝘴𝘱𝘰𝘯𝘴𝘰𝘳𝘦𝘥 𝘱𝘰𝘴𝘵
𝘈𝘭𝘭𝘦𝘳𝘨𝘺 𝘓𝘪𝘧𝘦 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘴 𝘢𝘭𝘭𝘦𝘳𝘨𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥 𝘵𝘰 𝘬𝘦𝘦𝘱 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥.
January 30, 2025 at 11:38 PM
🔗 The study is currently recruiting participants. To learn more and check your eligibility, visit- allergylife.com.au/iggenix
-𝘛𝘩𝘪𝘴 𝘪𝘴 𝘯𝘰𝘵 𝘢 𝘴𝘱𝘰𝘯𝘴𝘰𝘳𝘦𝘥 𝘱𝘰𝘴𝘵
𝘈𝘭𝘭𝘦𝘳𝘨𝘺 𝘓𝘪𝘧𝘦 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘴 𝘢𝘭𝘭𝘦𝘳𝘨𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥 𝘵𝘰 𝘬𝘦𝘦𝘱 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥.
-𝘛𝘩𝘪𝘴 𝘪𝘴 𝘯𝘰𝘵 𝘢 𝘴𝘱𝘰𝘯𝘴𝘰𝘳𝘦𝘥 𝘱𝘰𝘴𝘵
𝘈𝘭𝘭𝘦𝘳𝘨𝘺 𝘓𝘪𝘧𝘦 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢 𝘩𝘪𝘨𝘩𝘭𝘪𝘨𝘩𝘵𝘴 𝘢𝘭𝘭𝘦𝘳𝘨𝘺 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘦𝘥 𝘵𝘰 𝘬𝘦𝘦𝘱 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥.
🔬Study Overview-
• Name of Research Study: IgGenix ACCELERATE Peanut Study
• Area of Allergy Research: Food Allergies (Peanuts)
• Research for: Teens and Adults (15 to 55)
• Location of Study: Western Australia, New South Wales and Victoria
#peanutallergy #peanutallergies #iggenix
• Name of Research Study: IgGenix ACCELERATE Peanut Study
• Area of Allergy Research: Food Allergies (Peanuts)
• Research for: Teens and Adults (15 to 55)
• Location of Study: Western Australia, New South Wales and Victoria
#peanutallergy #peanutallergies #iggenix
January 30, 2025 at 11:38 PM
🔬Study Overview-
• Name of Research Study: IgGenix ACCELERATE Peanut Study
• Area of Allergy Research: Food Allergies (Peanuts)
• Research for: Teens and Adults (15 to 55)
• Location of Study: Western Australia, New South Wales and Victoria
#peanutallergy #peanutallergies #iggenix
• Name of Research Study: IgGenix ACCELERATE Peanut Study
• Area of Allergy Research: Food Allergies (Peanuts)
• Research for: Teens and Adults (15 to 55)
• Location of Study: Western Australia, New South Wales and Victoria
#peanutallergy #peanutallergies #iggenix